Therapy for influenza and acute respiratory viral infection in young and middle-aged schoolchildren: Effect of Ingavirin® on intoxication, fever, and catarrhal syndromes
https://doi.org/10.21508/1027-4065-2016-61-2-115-120
Abstract
The paper presents the clinical results of a double-blind, randomized, placebo-controlled multicenter phase III study evaluating the clinical efficacy and safety of Ingavirin® capsules 30 mg at a daily dose of 60 mg for the treatment of influenza and other acute respiratory viral infections (ARVI) in 7–12-year-old children.
The study included 310 children of both sexes. The study participants took Ingavirin® 60 mg/day or placebo for 5 days. The drug was shown to be effective in normalizing temperature and alleviating intoxication and catarrhal syndromes just at day 3 of therapy. Ingavirin® was demonstrated to considerably reduce the risk of bacterial complications of ARVI/influenza, which require antibiotic therapy, which is important for clinical use in children. This clinical trial has shown the high safety and tolerance of the drug. Ingavirin® contributes to accelerated virus elimination, shorter disease duration, and lower risk of complications.
About the Authors
I. M. Farber
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
N. A. Geppe
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
D. V. Reikhart
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
V. E. Nebolsin
"Farminterprayses"
Russian Federation
Russian Federation
V. S. Arnautov
“Valenta Farm”
Russian Federation
Moscow
Russian Federation
Moscow
A. A. Globenko
“Valenta Farm”
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Сведения об инфекционных и паразитарных заболеваниях за январь–декабрь 2009. Детские инфекции 2010; 1: 3. (Data on infectious and parasitic diseases for JanuaryDecember, 2009. Detskie infektsii 2010; 1: 3.)
2. Сведения об инфекционных и паразитарных заболеваниях за январь–декабрь 2010. Детские инфекции 2011; 2: 3. (Data on infectious and parasitic diseases for JanuaryDecember, 2010. Detskie infektsii 2011; 2: 3.)
3. Сведения об инфекционных и паразитарных заболеваниях за январь–декабрь 2014. Роспотребнадзор. http://www.rospotrebnadzor.ru (Data on infectious and parasitic diseases for January-December, 2014. Rospotrebnadzor. http://www.rospotrebnadzor.ru)
4. Отчет ВОЗ по гриппу за март 2014. http://www.who.int/mediacentre/factsheets/fs211/en/ (The report of WHO on flu for March, 2014. http://www.who.int/mediacentre/factsheets/fs211/en/)
5. Харламова Ф.С. Грипп у детей: лечение и профилактика осложнений. Лечащий врач 2007; 1: 23–28. (Kharlamova F.S. Flu at children: treatment and prevention of complications. Lechashhij vrach 2007; 1: 23–28.)
6. Учайкин В.Ф. Руководство по инфекционным болезням у детей. М: ГЭОТАР-МЕД 2002; 824. (Uchajkin V.F. The guide to infectious diseases at children. Moscow: GEHOTАR-MED 2002; 824.)
7. Государственный реестр лекарственных средств, ЛСР-006330/08 от 07.08.2008; http://www.grls.rosminzdrav.ru›grls.aspx (State register of medicines, LSR-006330/08,07.08.2008; http://www.grls.rosminzdrav.ru›grls.aspx)
8. Отчет по проведенному исследованию «Двойное слепое рандомизированное плацебо-контролируемое многоцентровое исследование по оценке клинической эффективности и безопасности препарата Ингавирин®, капсулы 30 мг, для лечения гриппа и других ОРВИ у детей в возрасте 13–17 лет». М, 2013; 122. (The report on the conducted research «Double blind randomized placebo – controlled multicenter research on an assessment of clinical efficiency and safety of a preparation Ingavirin®, capsules 30 mg, for treatment of flu and other SARS at children at the age of 13–17 years». Moscow, 2013; 122.)
9. Инструкция по медицинскому применению препарата Ингавирин®; http://www.slovari.yandex.ru Регистр лекарственных средств России. (Instruction on medical application of a preparation Ingavirin®; http://www.slovari.yandex.ru› Регистр лекарственных средств России.)
10. Отчет по проведенному исследованию «Двойное слепое рандомизированное плацебо-контролируемое многоцентровое исследование по оценке клинической эффективности и безопасности препарата Ингавирин®, капсулы 30 мг, для лечения гриппа и других ОРВИ у детей в возрасте 7–12 лет». М, 2015; 144. (The report on the conducted research «Double blind randomized placebo – controlled multicenter research on an assessment of clinical efficiency and safety of a preparation Ingavirin®, capsules 30 mg, for treatment of flu and other SARS at children at the age of 7–12 years». Moscow, 2015; 144.)
11. Национальный стандарт РФ «Надлежащая клиническая практика» ГОСТ Р52379-2005; http://www.medtran.ru/rus/trials/gost/52379-2005.htm (National Russian Federation standard “Good clinical practice” GОSТ Р52379-2005; http://www.medtran.ru/rus/trials/gost/52379-2005.htm)
Review
For citations:
Farber I.M., Geppe N.A., Reikhart D.V., Nebolsin V.E., Arnautov V.S., Globenko A.A. Therapy for influenza and acute respiratory viral infection in young and middle-aged schoolchildren: Effect of Ingavirin® on intoxication, fever, and catarrhal syndromes. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2016;61(2):115-120. (In Russ.) https://doi.org/10.21508/1027-4065-2016-61-2-115-120
Views:
2138
Email this article 